Pericytes, inflammation, and diabetic retinopathy

Benjamin G. Spencer; Jose J. Estevez; Ebony Liu; Jamie E. Craig; John W. Finnie

doi:10.1007/s10787-019-00647-9

Pericytes, inflammation, and diabetic retinopathy

Benjamin G. Spencer, Jose J. Estevez, Ebony Liu, Jamie E. Craig, John W. Finnie

Research output: Contribution to journal › Review article › peer-review

105 Citations (Scopus)

Abstract

Diabetic retinopathy (DR) is a frequent complication of diabetes mellitus, and a common cause of vision impairment and blindness in these patients, yet many aspects of its pathogenesis remain unresolved. Furthermore, current treatments are not effective in all patients, are only indicated in advanced disease, and are associated with significant adverse effects. This review describes the microvascular features of DR, and how pericyte depletion and low-grade chronic inflammation contribute to the pathogenesis of this common ophthalmic disorder. Existing, novel and investigational pharmacological strategies aimed at modulating the inflammatory component of DR and ameliorating pericyte loss to potentially improve clinical outcomes for patients with diabetic retinopathy, are discussed.

Original language	English
Pages (from-to)	697-709
Number of pages	13
Journal	INFLAMMOPHARMACOLOGY
Volume	28
Issue number	3
Early online date	5 Dec 2019
DOIs	https://doi.org/10.1007/s10787-019-00647-9
Publication status	Published - 1 Jun 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Diabetic retinopathy
Inflammation
Pericytes
Retina

Access to Document

10.1007/s10787-019-00647-9Licence: In Copyright

Cite this

@article{b4fea6119dc94d4ca704330a80e7d674,

title = "Pericytes, inflammation, and diabetic retinopathy",

abstract = "Diabetic retinopathy (DR) is a frequent complication of diabetes mellitus, and a common cause of vision impairment and blindness in these patients, yet many aspects of its pathogenesis remain unresolved. Furthermore, current treatments are not effective in all patients, are only indicated in advanced disease, and are associated with significant adverse effects. This review describes the microvascular features of DR, and how pericyte depletion and low-grade chronic inflammation contribute to the pathogenesis of this common ophthalmic disorder. Existing, novel and investigational pharmacological strategies aimed at modulating the inflammatory component of DR and ameliorating pericyte loss to potentially improve clinical outcomes for patients with diabetic retinopathy, are discussed.",

keywords = "Diabetic retinopathy, Inflammation, Pericytes, Retina",

author = "Spencer, {Benjamin G.} and Estevez, {Jose J.} and Ebony Liu and Craig, {Jamie E.} and Finnie, {John W.}",

year = "2020",

month = jun,

day = "1",

doi = "10.1007/s10787-019-00647-9",

language = "English",

volume = "28",

pages = "697--709",

journal = "INFLAMMOPHARMACOLOGY",

issn = "0925-4692",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "3",

}

TY - JOUR

T1 - Pericytes, inflammation, and diabetic retinopathy

AU - Spencer, Benjamin G.

AU - Estevez, Jose J.

AU - Liu, Ebony

AU - Craig, Jamie E.

AU - Finnie, John W.

PY - 2020/6/1

Y1 - 2020/6/1

N2 - Diabetic retinopathy (DR) is a frequent complication of diabetes mellitus, and a common cause of vision impairment and blindness in these patients, yet many aspects of its pathogenesis remain unresolved. Furthermore, current treatments are not effective in all patients, are only indicated in advanced disease, and are associated with significant adverse effects. This review describes the microvascular features of DR, and how pericyte depletion and low-grade chronic inflammation contribute to the pathogenesis of this common ophthalmic disorder. Existing, novel and investigational pharmacological strategies aimed at modulating the inflammatory component of DR and ameliorating pericyte loss to potentially improve clinical outcomes for patients with diabetic retinopathy, are discussed.

AB - Diabetic retinopathy (DR) is a frequent complication of diabetes mellitus, and a common cause of vision impairment and blindness in these patients, yet many aspects of its pathogenesis remain unresolved. Furthermore, current treatments are not effective in all patients, are only indicated in advanced disease, and are associated with significant adverse effects. This review describes the microvascular features of DR, and how pericyte depletion and low-grade chronic inflammation contribute to the pathogenesis of this common ophthalmic disorder. Existing, novel and investigational pharmacological strategies aimed at modulating the inflammatory component of DR and ameliorating pericyte loss to potentially improve clinical outcomes for patients with diabetic retinopathy, are discussed.

KW - Diabetic retinopathy

KW - Inflammation

KW - Pericytes

KW - Retina

UR - http://www.scopus.com/inward/record.url?scp=85074010097&partnerID=8YFLogxK

U2 - 10.1007/s10787-019-00647-9

DO - 10.1007/s10787-019-00647-9

M3 - Review article

C2 - 31612299

AN - SCOPUS:85074010097

SN - 0925-4692

VL - 28

SP - 697

EP - 709

JO - INFLAMMOPHARMACOLOGY

JF - INFLAMMOPHARMACOLOGY

IS - 3

ER -

Pericytes, inflammation, and diabetic retinopathy

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this